NPR: 20% of employer plans cover GLP-1s

NPR reported on May 19 that roughly 20% of employer health plans cover GLP-1 drugs for weight loss, even as many employers that added the benefit are finding the budget math tougher than expected. The report centered on a simple question: whether paying for drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound now will lower other medical costs later. (npr.org) So far, employer surveys and benefit advisers say the answer is not showing up clearly in claims data. Instead, drug spending is arriving immediately, while any savings from fewer obesity-related complications may take longer to appear. (businessgrouphealth.org) ### Why are employers covering these drugs in the first place? GLP-1 drugs were originally developed for diabetes, but newer versions have become widely used for obesity because they can produce substantial weight loss. (businessgrouphealth.org) Employers have been under pressure from workers to cover them, and some benefit managers viewed that coverage as a way to improve health, retention and employee satisfaction. PHTI, a nonprofit that evaluates health technologies, said in a December 2025 employer report that demand for GLP-1 coverage was “soaring” even though fewer than one in five employers covered the drugs for weight loss. Mercer said in a July 2025 briefing that 44% of employers with 500 or more employees covered weight-loss medications in 2024, rising to 64% among employers with 20,000 or more workers. (npr.org) That large-employer figure helps explain why headline numbers can look different depending on whether the data refer to all employer plans or only big companies. ### Why isn’t the cost case working the way some employers hoped? PHTI said early evidence on medical-cost offsets is mixed, but “the evidence is unanimous” that GLP-1s currently increase total healthcare spending for employers. The group said drug costs exceed reductions in other medical costs over the three- to four-year period in which most workers remain covered by an employer plan. (phti.org) Mercer said the drugs are priced at more than $1,000 a month before rebates and have become two of the fastest-growing contributors to pharmacy spending. That creates a timing problem for employers: pharmacy costs hit quickly, while avoided costs from fewer obesity-related conditions may take years to materialize, if they materialize at all within the period an employee stays on a company plan. (mercer.com) ### What are employers seeing in their own claims and budgets? Business Group on Health said on May 2026 that nearly eight in 10 employers reported GLP-1s are driving increases in their healthcare costs. Among employers that cover GLP-1s for weight management, more than half said they expect meaningful clinical benefits, but few said they have yet seen proof in aggregated claims, such as lower obesity rates or fewer bariatric surgeries. (phti.org) KFF said in an October 2025 analysis that conversations with employers across more than 100 companies found many were considering scaling back coverage or tightening requirements because of cost concerns. NPR’s May 19 report fits that broader pattern: employers may believe the drugs help individual workers, but many are still struggling to show near-term savings for the health plan. (mercer.com) ### How are companies trying to control the spending? Business Group on Health said employers that do cover GLP-1s are relying on utilization controls, including biometric verification of eligibility, required participation in weight-management programs, limits on which clinicians can prescribe, and formulary exclusions for some drugs. (businessgrouphealth.org) Those tools are meant to narrow use to workers who meet plan criteria and to reduce inappropriate prescribing. Mercer said employers are also asking pharmacy benefit managers how they would handle new indications beyond obesity, including cardiovascular risk reduction and sleep apnea. As the list of approved uses grows, employers have to decide whether a drug that began as a weight-loss debate should be treated instead as a broader chronic-disease benefit. (kff.org) ### What happens next as 2027 planning starts? Business Group on Health said only 72% of employers that currently cover GLP-1s for weight management expect to continue that coverage in 2027, while 10% said they likely will not. The same survey found 87% expect oral GLP-1 drugs to increase demand further, and only 9% expect prices to fall. (businessgrouphealth.org) Mercer said 77% of large employers view managing GLP-1 costs as extremely or very important as they make benefit decisions for 2026 and beyond. That means the next phase of this story is likely to show up in open-enrollment materials, formulary rules and employer benefit committees as companies decide how much access they are willing to finance. (mercer.com) (businessgrouphealth.org)